Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Liu, M. C.; Hillman, D. W.; Frith, A. E.; Lyss, A. P.; Weckstein, D. J.; Moreno-Aspitia, A.; Le-Lindqwister, N.; Isaacs, C.; Wender, D. B.; Lewis, D. A.; Cole, J. T.; Jaslowski, A. J.; Rowland, K. M.; Openshaw, T. H.; Friday, B. E. B.; Fleming, G. F.; Asmus, E.; Rogak, L. J.; Basch, E. M.; Dueck, A. C. |
| Abstract Title: | Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368300189 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.1016 |
| Notes: | Meeting Abstract: 1016 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
